Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: Results of the ECOG E2A02 trial

A. Dispenzieri, S. Jacobus, D. H. Vesole, N. Callandar, R. Fonseca, P. R. Greipp

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: Results of the ECOG E2A02 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences